Note: This story was updated on Jan. 14, 2021, to note that DA01 is derived from ESCs and that the trial will take place at MSK in New York. ... Read more
A diet rich in antioxidants like vitamin C and E may lower a person’s risk of developing Parkinson’s disease, a large long-term study suggests. Titled “Dietary antioxidants and the ... Read more
Xadago (safinamide) — approved as an add-on therapy to ease “off periods” that can accompany levodopa — may also help with urinary symptoms in people with Parkinson’s disease, a small study reports. These ... Read more
Adamas Pharmaceuticals has acquired global rights to the Parkinson’s disease medication Osmolex ER (amantadine hydrochloride), used to treat motor symptoms, including those caused by other therapies. The purchase, worth ... Read more
Researchers have developed a faster method of measuring the rate at which alpha-synuclein protein forms toxic clumps that reliably distinguishes people with Parkinson’s disease from those without the condition. ... Read more
A first patient has been dosed in IMAC Holdings’ Phase 1 clinical trial evaluating its investigational umbilical cord-derived mesenchymal stem cells (MSCs) as a potential treatment for bradykinesia, a common motor ... Read more
The G. Harold and Leila Y. Mathers Foundation has awarded a three-year grant to a team of researchers at the Massachusetts Institute of Technology’s (MIT) Picower Institute for Learning and Memory ... Read more
People with early Parkinson’s disease are at a higher risk of developing later cognitive problems if they are overweight, have symptoms of depression or anxiety, or have sleep issues ... Read more
An alternative method of recycling mitochondria — the cell’s powerhouses — that involves pushing damaged mitochondria out of cells, seems to play a role in Parkinson’s disease, according to a ... Read more
Older age, male sex, and a family history of Parkinson’s disease appear to associate with a higher risk of developing Parkinson’s later in life, according to an Italian study. ... Read more
